Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142

K. S. Sink, K. N. Segovia, J. Sink, P. A. Randall, L. E. Collins, M. Correa, E. J. Markus, V. K. Vemuri, A. Makriyannis, J. D. Salamone

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Cannabinoid CB1 inverse agonists suppress food-motivated behaviors, but may also induce psychiatric effects such as depression and anxiety. To evaluate behaviors potentially related to anxiety, the present experiments assessed the CB1 inverse agonist AM251 (2.0-8.0 mg/kg), the CB1 antagonist AM4113 (3.0-12.0 mg/kg), and the benzodiazepine inverse agonist FG-7142 (10.0-20.0 mg/kg), using the open field test and the elevated plus maze. Although all three drugs affected open field behavior, these effects were largely due to actions on locomotion. In the elevated plus maze, FG-7142 and AM251 both produced anxiogenic effects. FG-7142 and AM251 also significantly increased c-Fos activity in the amygdala and nucleus accumbens shell. In contrast, AM4113 failed to affect performance in the plus maze, and did not induce c-Fos immunoreactivity. The weak effects of AM4113 are consistent with biochemical data showing that AM4113 induces little or no intrinsic cellular activity. This research may lead to the development of novel appetite suppressants with reduced anxiogenic effects.

Original languageEnglish (US)
Pages (from-to)112-122
Number of pages11
JournalEuropean Neuropsychopharmacology
Volume20
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Cite this